An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

NCT03735628 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)
Head and Neck Squamous Cell Carcinoma (HNSCC)
Hepatocellular Carcinoma (HCC)

Interventions

DRUG: Copanlisib
DRUG: Nivolumab

Sponsor

Bayer